69P PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer
H. Kim
◽
J. Kim
◽
S. Byeon
◽
J.Y. Hong
◽
J. Lee
◽
...
2018 ◽
Vol 39
(3)
◽
pp. 252-259
◽
Maria I. Braghiroli
◽
José M. Mota
◽
Paulo S. Duarte
◽
Tiago O. Morita
◽
Giovanni M. Bariani
◽
...
Kyoichi Kaira
◽
Yutaka Sunose
◽
Yasuhiro Ohshima
◽
Noriko S Ishioka
◽
Kazuhisa Arakawa
◽
...
2017 ◽
Vol 28
◽
pp. iii76
Kabsoo Shin
◽
Ah Lee Myung
2021 ◽
Vol 35
(1)
◽
pp. 499-505
HYERA KIM
◽
SEUNG TAE KIM
◽
KWAI HAN YOO
◽
JUNG YONG HONG
◽
YOUNG SUK PARK
◽
...
Hyera Kim
◽
Jinchul Kim
◽
Seonggyu Byeon
◽
Jung Yong Hong
◽
Jeeyun Lee
◽
...
2002 ◽
Vol 29
(6U)
◽
pp. 51-53
◽
J Harder
◽
O Waiz
◽
M Geissler
◽
HE Blum
◽
A Schmitt-Gräff
◽
...
C Mayr
◽
A Wagner
◽
D Neureiter
◽
M Pichler
◽
M Ritter
◽
...
Orphan designation: (5R,5aR,8aR,9S)-9-[[4,6-O-[(R)-Ethylidene]-β-D-glucopyranosyl]-oxy]-5-(4-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl}oxy)-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydroisobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one (etoposide toniribate), Treatment of biliary tract cancer